Exclusive Summary

• - No patent barrier and long market history enable fast distribution-led entry in markets that recognize the class
• - Demand pools are in liver-disease support and chemotherapy-related toxicity management; large patient base but mostly as adjunct
• - Not on WHO EML and not routinely recommended by major Western guidelines, so focus on Asia/LATAM/CIS where hepatoprotective injectables are accepted
• - Crowded in Asia/emerging markets; differentiation via ICH-quality CTD, Zone IVb stability, and a higher 1.2 g strength
• - Pricing can undercut legacy brands by 30–70%, with the 1.2 g pack reducing administration steps and total use cost